Rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis triggered by a 23-valent pneumococcal polysaccharide vaccine

Autoimmun Rev. 2023 May;22(5):103307. doi: 10.1016/j.autrev.2023.103307. Epub 2023 Feb 24.

Authors

Koji Suzuki¹, Mitsuhiro Akiyama¹, Yasushi Kondo¹, Shuntaro Saito¹, Jun Kikuchi¹, Hironari Hanaoka¹, Yuko Kaneko²

Affiliations

¹ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
² Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address: ykaneko.z6@keio.jp.

PMID: 36842726
DOI: 10.1016/j.autrev.2023.103307

No abstract available

Publication types

Letter

MeSH terms

Dermatomyositis* / complications
Disease Progression
Humans
Immunosuppressive Agents
Lung Diseases, Interstitial* / complications
Pneumococcal Vaccines / therapeutic use

Substances

Immunosuppressive Agents
Pneumococcal Vaccines

Supplementary concepts

Amyopathic dermatomyositis